Showing 201 - 220 results of 146,577 for search '(( 10 ((mg decrease) OR (a decrease)) ) OR ( 50 ((ns decrease) OR (mean decrease)) ))', query time: 0.77s Refine Results
  1. 201
  2. 202
  3. 203
  4. 204
  5. 205
  6. 206
  7. 207
  8. 208
  9. 209

    Damage accumulation decreases elongation rates and displaces growth equilibrium. by Audrey Menegaz Proenca (845486)

    Published 2019
    “…<p>All panels depict MG1655 wild-type <i>E</i>. <i>coli</i>. (A) Exposure to phototoxic damage led to decreasing elongation rates in all treatment levels (length of exposure, every 2 min: 70 ms, 700 ms, 1 s, 1.5 s, 3 s). …”
  10. 210

    Boron Leaching Decreases withIncreases on Soil pH by Alessandra Aparecida de Sá (12700698)

    Published 2022
    “…The experiment was carried out in the laboratory in 2012, and treatments consisted of a factorial combination of two rates of liming (without and with lime to raise the soil pH to 6.0) and five rates of B (0, 10, 20, 50 and 100 mg kg-1, as boric acid). …”
  11. 211
  12. 212
  13. 213
  14. 214
  15. 215
  16. 216
  17. 217
  18. 218

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  19. 219

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  20. 220